Your browser doesn't support javascript.
loading
Interstitial lung disease in primary Sjögren's syndrome.
Roca, F; Dominique, S; Schmidt, J; Smail, A; Duhaut, P; Lévesque, H; Marie, I.
Affiliation
  • Roca F; Department of Internal Medicine, Rouen University Hospital, Rouen, France; INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France.
  • Dominique S; Department of Pneumology, Rouen University Hospital, Rouen, France.
  • Schmidt J; Department of Internal Medicine, Amiens University Hospital, Amiens, France.
  • Smail A; Department of Internal Medicine, Amiens University Hospital, Amiens, France.
  • Duhaut P; Department of Internal Medicine, Amiens University Hospital, Amiens, France.
  • Lévesque H; Department of Internal Medicine, Rouen University Hospital, Rouen, France; INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France.
  • Marie I; Department of Internal Medicine, Rouen University Hospital, Rouen, France; INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France. Electronic address: isabelle.marie@chu-rouen.fr.
Autoimmun Rev ; 16(1): 48-54, 2017 Jan.
Article in En | MEDLINE | ID: mdl-27682894
ABSTRACT
Interstitial lung disease (ILD) has been reported in 3 to 11% of patients with primary Sjögren's syndrome (pSS). The aims of this retrospective multicenter study were to 1) analyze characteristics and outcome of ILD in pSS; and 2) evaluate predictive factors associated with ILD onset and deterioration. Twenty-one of 263 patients with pSS (8%) developed ILD. ILD onset preceded pSS diagnosis (n=5), was concurrently identified in association with pSS (n=6) and developed after pSS onset (n=9). Presenting ILD manifestations were acute/subacute (n=11) onset of ILD, symptomatic progressive onset of ILD (n=5), and asymptomatic patients exhibiting abnormalities consistent with ILD on PFTs and HRCT-scan (n=5). ILD therapy included steroids (n=21), cyclophosphamide (n=1), azathioprine (n=4) and rituximab (n=1). The course of ILD was as follows improvement (15.8%), stabilization (47.4%) or deterioration (36.8%). Predictive parameters of ILD onset were older age (p=0.044), Raynaud's phenomenon (p=0.001) and esophageal involvement (p=0.001). Factors associated with ILD deterioration were older age (p=0.038) and esophageal involvement (p=0.038). Thus, this study underscores the poor outcome of ILD during pSS; thus, systematic screening of pulmonary involvement is required in pSS patients, resulting in both diagnosis and management at early stage of ILD. We also suggest that patients presenting predictive factors of ILD deterioration may need a closer follow-up and a more aggressive therapy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sjogren's Syndrome / Lung Diseases, Interstitial Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Autoimmun Rev Journal subject: ALERGIA E IMUNOLOGIA Year: 2017 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sjogren's Syndrome / Lung Diseases, Interstitial Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Autoimmun Rev Journal subject: ALERGIA E IMUNOLOGIA Year: 2017 Document type: Article Affiliation country: France